Accessibility Menu
Botanix Pharmaceuticals logo

Botanix Pharmaceuticals(ASX) BOT

Market CapA$60.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-27%
5 Year-72%
1 Year-86%
1 Month-12%
A$0.02
+0.00%
+0.00Today
Botanix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.022026-08-13
Botanix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.35%AUD 0.022026-08-06
1 month-12%AUD 0.032026-07-14
3 month-21.43%AUD 0.032026-05-15
Year to date-83.7%AUD 0.142025-12-31
1 year-85.81%AUD 0.162025-08-13
3 year-87.06%AUD 0.172023-08-14
5 year-71.79%AUD 0.082021-08-13
Since inception-26.67%AUD 0.032016-07-15

Botanix Pharmaceuticals Financials at a Glance

Market Cap

A$60.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$23.99M

Net Income (TTM)

-A$127.99M

EPS (TTM)

-A$0.05

P/E Ratio

-0.47

Dividend

A$0.00

Beta (Volatility)

-0.01 (Low)

Price

A$0.02

Volume

644,094

Open

A$0.02

Previous Close

A$0.02

Daily Range

A$0.02 - A$0.02

52-Week Range

A$0.02 - A$0.17

Estimated Earnings Date

Aug 28, 2026

BOT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited is an Australian biotechnology company focused on developing innovative dermatological and antimicrobial therapeutic agents. The company aims to address common skin conditions and infections through its advanced product pipeline.

Products and Services
  • Sofpironium Bromide for primary axillary hyperhidrosis
  • BTX 1503, a transdermal gel for severe acne
  • BTX 1801 targeting Staphylococcus aureus infections
Growth Outlook
  • Successful Phase 3 trials for Sofpironium Bromide enhance market potential
  • BTX 1503 has completed Phase II trials, indicating strong development progress
  • Expansion into new therapeutic areas with BTX 1702 and BTX 1204A
Financial Highlights
  • Recent quarterly revenue of AUD 16.5 million shows significant growth
  • Cash reserves of AUD 31.6 million provide operational stability
  • Current ratio of 2.56 indicates strong liquidity position
Botanix Pharmaceuticals Limited is positioned to capitalize on its innovative product pipeline and growing market demand for effective dermatological treatments. The company's focus on research and development, combined with its recent financial performance, suggests a promising trajectory for future growth. Investors may find the company's advancements in clinical trials and solid cash position appealing as it navigates the competitive biotechnology landscape.
AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

CEO

Howie McKibbon, PharmD

Headquarters

Leederville, WA 6007, AU

BOT Financials

Key Financial Metrics (TTM)

Gross Margin

-118.23%

Operating Margin

-380.62%

Net Income Margin

-404.72%

Return on Equity

-131.13%

Return on Capital

-70.99%

Return on Assets

-89.99%

Earnings Yield

-2.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$60.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.73B

Volume

644.09K

Avg. Volume

12.31M

Financials (TTM)

Gross Profit

-A$27.73M

Operating Income

-A$124.26M

EBITDA

-A$121.48M

Operating Cash Flow

-A$115.59M

Capital Expenditure

-A$365.23K

Free Cash Flow

-A$115.96M

Cash & ST Invst.

A$31.61M

Total Debt

A$30.67M

Botanix Pharmaceuticals Performance Analysis

Botanix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 914,973N/A
20242024-06-30AUD 1,034,55813.1%
20252025-06-30AUD 6,482,824526.6%
Botanix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30347.7%
Q22024-12-31-77.7%
Q42025-06-301333.2%
Q22025-12-31205.0%
Botanix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.01-41.5%
20242024-06-30AUD -0.0116.5%
20252025-06-30AUD -0.05408.7%
Botanix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-42.1%
Q22024-12-31-214.8%
Q42025-06-30-74.1%
Q22025-12-3142.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$16.51M

+4267.4%

Gross Profit

-A$28.76M

-850.8%

Gross Margin

-1.74%

N/A

Market Cap

A$60.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$5.47M

N/A

Employees

11

N/A

Net Income

-A$33.20M

-507.2%

EBITDA

-A$32.43M

-487.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$31.61M

+72.6%

Total Debt

A$30.67M

N/A

Accounts Receivable

A$5.70M

+2497.1%

Inventory

A$27.51M

+778.3%

Long Term Debt

A$17.54M

N/A

Short Term Debt

A$13.13M

N/A

Return on Assets

-89.99%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

-A$32.64M

-76.1%

Operating Cash Flow

-A$32.64M

-768.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAR.AXParadigm Biopharmaceuticals Limited
A$0.18+0.00%
RCE.AXRecce Pharmaceuticals Ltd
A$0.38+1.33%
ATH.AXAlterity Therapeutics Limited
A$0.54+0.00%
ACW.AXActinogen Medical Limited
A$0.04-4.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About BOT

What is the current price of Botanix Pharmaceuticals?

Botanix Pharmaceuticals is trading at A$0.02 per share.

What is the 52-week range for Botanix Pharmaceuticals?

Over the past 52 weeks, Botanix Pharmaceuticals has traded between A$0.02 and A$0.17.

How much debt does Botanix Pharmaceuticals have?

As of the most recent reporting period, Botanix Pharmaceuticals reported total debt of A$32.11M.

How much cash does Botanix Pharmaceuticals have on hand?

Botanix Pharmaceuticals reported A$64.97M in cash and cash equivalents in its most recent financial results.

What is Botanix Pharmaceuticals’s dividend yield?

Botanix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.